Clinically, tocilizumab, a humanized monoclonal antibody targeting IL-6R, has improved symptoms and prognosis in cachectic patients, with Phase II trials in lung cancer confirming its ability to alleviate anorexia and weight loss (149, 156). Here, IL6R is linked to lung carcinoma.